You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):擬從NOVITA獲得Fascin蛋白抑制劑獨佔許可在大中華區的相關權益
格隆匯 07-20 20:05

格隆匯7月20日丨華潤雙鶴(600062.SH)公佈,公司屆董事會第二次會議決議,審議通過關於公司與NOVITA簽署Fascin蛋白抑制劑項目協議的議

為貫徹落實公司“十四五”戰略,加快創新轉型與質量發展,拓展公司在腫瘤領域產品的研發管線佈局,提升整體研發創新能力,董事會同意公司通過創新事業部從Novita Pharmaceuticals, Inc.(諾維塔製藥有限公司,簡稱“NOVITA)獲得Fascin蛋白抑制劑獨佔許可在大中華區(中國大陸、港澳台)的開發、生產及商業化權益,並使用、獲得相關知識產權;同意以不超過1.15億美元支付首付款及3個適應症里程碑付款,後續項目開展中如超出前述支出,再行履行審批程序;授權經營層辦理簽署相關《獨佔許可協議》和《專利轉讓協議》等具體事宜。

Fascin蛋白抑制劑為NOVITA公司開發的全新小分子化合物,前期研究發現能夠有效抑制Fascin蛋白從而降低腫瘤侵襲或腫瘤轉移,未來可作為一種潛在控制腫瘤轉移的口服藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account